Loading clinical trials...
Loading clinical trials...
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell trans...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
New York Medical College
NCT06390319 · T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, and more
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT05376111 · T-cell Acute Lymphoblastic Leukemia, Recruiting
NCT05679895 · T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma
NCT06934382 · T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Phoenix Children's Hospital
Phoeniz, Arizona
Loma Linda University Children's Hospital
Loma Linda, California
University of California
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions